How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
19
APVO Quote, Financials, Valuation and Earnings
Last price:
$6.65
Seasonality move
:
-19.22%
Day range:
$7.07 - $7.84
52-week range:
$6.88 - $1,609.19
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.04x
P/B ratio:
7.31x
Volume:
94.7K
Avg. volume:
317.8K
1-year change:
-99.52%
Market cap:
$127.1M
Revenue:
--
EPS (TTM):
-$185.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
-- | -$8.10 | -- | -99.48% | $21.00 |
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -- | -- | -- | $10.00 |
|
JNJ
Johnson & Johnson
|
$24.1B | $2.46 | 7.79% | -40.82% | $230.63 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.93 | 35.83% | 148.28% | $1,150.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
$7.54 | $21.00 | $127.1M | -- | $0.00 | 0% | 0.04x |
|
DRMA
Dermata Therapeutics, Inc.
|
$2.02 | $10.00 | $2.1M | -- | $0.00 | 0% | -- |
|
JNJ
Johnson & Johnson
|
$230.75 | $230.63 | $555.9B | 20.89x | $1.30 | 2.23% | 5.95x |
|
LLY
Eli Lilly & Co.
|
$1,044.13 | $1,150.00 | $934.5B | 51.64x | $1.50 | 0.58% | 16.02x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.71 | $0.85 | $215.8M | 2.87x | $0.80 | 0% | 3.32x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
18.66% | 2.255 | 4.74% | 3.75x |
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -0.561 | -- | 4.20x |
|
JNJ
Johnson & Johnson
|
36.62% | -0.049 | -- | 0.71x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.536 | 6.22% | 0.65x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | -2.840 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
-$49K | -$7.6M | -260.27% | -442.03% | -- | -$6.7M |
|
DRMA
Dermata Therapeutics, Inc.
|
-- | -$1.8M | -190.86% | -190.86% | -- | -$1.8M |
|
JNJ
Johnson & Johnson
|
$17.8B | $5.6B | 21.7% | 33.27% | 22.76% | $8B |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
Aptevo Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns APVO or DRMA?
Dermata Therapeutics, Inc. has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of --. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat Dermata Therapeutics, Inc.'s return on equity of -190.86%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M DRMADermata Therapeutics, Inc.-- -$1.65 $4M -
What do Analysts Say About APVO or DRMA?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 4913.26%. On the other hand Dermata Therapeutics, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 395.05%. Given that Aptevo Therapeutics, Inc. has higher upside potential than Dermata Therapeutics, Inc., analysts believe Aptevo Therapeutics, Inc. is more attractive than Dermata Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 DRMADermata Therapeutics, Inc.0 0 0 -
Is APVO or DRMA More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.495, which suggesting that the stock is 49.543% more volatile than S&P 500. In comparison Dermata Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock APVO or DRMA?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dermata Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. Dermata Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or DRMA?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than Dermata Therapeutics, Inc. quarterly revenues of --. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than Dermata Therapeutics, Inc.'s net income of -$1.7M. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while Dermata Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus -- for Dermata Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M DRMADermata Therapeutics, Inc.-- -- -- -$1.7M
-
Which has Higher Returns APVO or JNJ?
Johnson & Johnson has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of 20.83%. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M JNJJohnson & Johnson72.39% $2.10 $125.1B -
What do Analysts Say About APVO or JNJ?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 4913.26%. On the other hand Johnson & Johnson has an analysts' consensus of $230.63 which suggests that it could fall by -0.05%. Given that Aptevo Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Aptevo Therapeutics, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 JNJJohnson & Johnson9 10 0 -
Is APVO or JNJ More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.495, which suggesting that the stock is 49.543% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.350, suggesting its less volatile than the S&P 500 by 64.977%.
-
Which is a Better Dividend Stock APVO or JNJ?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.23% to investors and pays a quarterly dividend of $1.30 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios APVO or JNJ?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than Johnson & Johnson's net income of $5.1B. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus 5.95x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M JNJJohnson & Johnson5.95x 20.89x $24.6B $5.1B
-
Which has Higher Returns APVO or LLY?
Eli Lilly & Co. has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of 31.72%. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About APVO or LLY?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 4913.26%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,150.00 which suggests that it could grow by 10.14%. Given that Aptevo Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Aptevo Therapeutics, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 LLYEli Lilly & Co.17 7 0 -
Is APVO or LLY More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.495, which suggesting that the stock is 49.543% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock APVO or LLY?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios APVO or LLY?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus 16.02x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M LLYEli Lilly & Co.16.02x 51.64x $17.6B $5.6B
-
Which has Higher Returns APVO or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of -255.85%. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About APVO or NBY?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 4913.26%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -50.29%. Given that Aptevo Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Aptevo Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is APVO or NBY More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.495, which suggesting that the stock is 49.543% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.135, suggesting its less volatile than the S&P 500 by 86.499%.
-
Which is a Better Dividend Stock APVO or NBY?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or NBY?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus 3.32x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M NBYNovaBay Pharmaceuticals, Inc.3.32x 2.87x $521K -$1.3M
-
Which has Higher Returns APVO or PTN?
Palatin Technologies has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of --. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About APVO or PTN?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 4913.26%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Aptevo Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Aptevo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is APVO or PTN More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.495, which suggesting that the stock is 49.543% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock APVO or PTN?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or PTN?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Aptevo Therapeutics, Inc.'s net income of -$9M is higher than Palatin Technologies's net income of --. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M PTNPalatin Technologies-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 43x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 43x
Alerts
Sell
49
HYMC alert for Feb 3
Hycroft Mining Holding Corp. [HYMC] is up 19.68% over the past day.
Buy
67
FBRX alert for Feb 3
Forte Biosciences, Inc. [FBRX] is down 0.2% over the past day.
Buy
72
BNR alert for Feb 3
Burning Rock Biotech Ltd. [BNR] is down 15.43% over the past day.
